In Switzerland, a peptide sold for its effect on the body is a medicine.

That one fact settles most of what follows. It decides who may prescribe a peptide, who may prepare it, where it may be bought, and what happens to a parcel from an online shop when it reaches the border. This article sets out the position as Swissmedic, the Swiss Agency for Therapeutic Products, has stated it in 2026, and what it means for anyone weighing a treatment.

What peptides are, and which of them are medicines

Peptides are short chains of amino acids. The body produces many of them as signaling molecules, and some of the most important medicines of the past century belong to this class. Insulin is a peptide. So are the GLP-1 medicines now prescribed for diabetes and weight management. Products like these have been through clinical trials, they hold a Swissmedic authorization, and, as Swissmedic puts it, they are available only on prescription and must be used under medical supervision.

A second group circulates online: substances such as BPC-157, Epitalon, CJC-1295 or Ipamorelin, sold as injectable “research chemicals” and promoted for healing, longevity or performance. Swissmedic’s position on this group leaves no room for interpretation. Peptide-like substances advertised on websites, social media or messaging services are often inadequately tested for use in humans and not authorized as medicinal products in Switzerland. The sale of BPC-157, which Swissmedic has not approved, is illegal.

What Swiss law says

A ready-to-use medicine needs a Swissmedic authorization before it may be placed on the market. That is the rule of the Therapeutic Products Act, and Swissmedic restates it in the first line of its guidance on pharmacy preparations.

The law allows one route around a missing authorization, and it runs through the physician. A public or hospital pharmacy may prepare a medicine for a named patient on the basis of a medical prescription. Swissmedic calls this the formula magistralis. Such a preparation may be made and dispensed only against a prescription, and it may not be advertised or distributed. Because no authority has assessed it for quality, efficacy and safety, the duty of care in prescribing, dispensing and use carries the weight an authorization would otherwise carry. For peptides, the pharmacy may work only from raw materials approved by Swissmedic, and patented medicines, weight-loss drugs among them, may not be compounded at all.

Beyond authorized products and prescription-based preparations, the law is blunt. Anyone who distributes unauthorized medicines in Switzerland, or offers them by dropshipping to Swiss customers, is acting illegally, and distribution can lead to criminal proceedings. Labeling a product as a “research chemical”, as “not for human use” or as a “nutritional supplement” changes nothing if the product is destined for human use.

Importing for your own use has its own limits. Private individuals may bring a month’s supply of medicines into Switzerland for their own use, but not for anyone else. Doping substances fall under different rules, and Swissmedic says a zero-tolerance approach is normally taken. A withheld shipment that poses a health risk or comes from an illegal source is destroyed, and the recipient pays administrative costs of at least CHF 540.

What the June 2026 campaign found

On 22 June 2026, Swissmedic, the Federal Office for Customs and Border Security and Swiss Sport Integrity ran a targeted campaign against illegally imported peptides. 46 packages with dubious peptide preparations were found and checked. Of these, 23 were retained: 21 were classified as doping agents and two as medicinal products. Around 80 percent of the checked packages had been sent from Poland.

Swissmedic’s warning after the campaign concerned injectables above all. Where sterility, stability or composition cannot be guaranteed, the consequences for health can be serious. Its advice to the public is not to order or use peptides or comparable substances of unknown origin, and to see a doctor if symptoms appear after use.

Why the prescription matters

A prescription is not paperwork. It is the moment a physician takes responsibility: for the diagnosis that justifies a treatment, for the choice between an authorized product and, where the law permits it, a pharmacy preparation, for the dose, for the monitoring, and for the record that follows you to the next doctor. Swiss law asks for the same on the pharmacy’s side: prescribing and dispensing a preparation must follow the recognized rules of medical and pharmaceutical science.

For the substances promoted online, that responsibility has nothing to rest on. Most have not been tested in humans, or only at small scale, and reported side effects include nausea, water retention and abnormal blood vessel growth. A prescription cannot replace missing evidence, and the law does not let a pharmacy fill the gap with unapproved raw material.

What this means in practice

  • Ask one question first: is this an authorized medicine in Switzerland, or a preparation a pharmacy makes for me on prescription? If it is neither, it cannot lawfully be sold to you here.
  • Expect a diagnosis before a prescription, and expect the physician to say which product, which dose and which follow-up. That is what the duty of care looks like from your side.
  • Read “research chemical” and “not for human use” as what they are: the product has not been cleared for people, and the label changes nothing about its legal status.
  • Do not order peptides from unknown suppliers on websites, social media or messaging services. When you bring medicines into Switzerland for your own use, a month’s supply is the limit.

Where Veltracon Medical stands

Veltracon Medical is not a pharmacy and does not supply peptides or any other medicine. What a membership gives you is access: to physicians who can tell you whether a treatment is indicated at all, to a second opinion when a clinic abroad has proposed one, and to Swiss clinics that work inside the framework described here. If peptide therapy is on your mind, the useful first step is a consultation, not an order. Contact us if you would like to talk it through with a physician.

About this article

This text replaces the version published on 15 July 2025, which presented peptide therapy as an anti-aging strategy. It was revised in September 2026 to set out the legal position in Switzerland. It is general information, not medical advice.

Sources:

Originally published on veltracon-medical.com, July 15, 2025.